Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Validation of the Diabetes Prevention Trial-Type 1 Risk Score in the TrialNet Natural History Study.

Sosenko JM, Skyler JS, Mahon J, Krischer JP, Beam CA, Boulware DC, Greenbaum CJ, Rafkin LE, Cowie C, Cuthbertson D, Palmer JP; Type 1 Diabetes TrialNet and Diabetes Prevention Trial-Type 1 Study Groups.

Diabetes Care. 2011 Aug;34(8):1785-7. doi: 10.2337/dc11-0641. Epub 2011 Jun 16.

2.

Use of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS) for improving the accuracy of the risk classification of type 1 diabetes.

Sosenko JM, Skyler JS, Mahon J, Krischer JP, Greenbaum CJ, Rafkin LE, Beam CA, Boulware DC, Matheson D, Cuthbertson D, Herold KC, Eisenbarth G, Palmer JP; Type 1 Diabetes TrialNet and Diabetes Prevention Trial-Type 1 Study Groups.

Diabetes Care. 2014 Apr;37(4):979-84. doi: 10.2337/dc13-2359. Epub 2014 Feb 18.

3.

The application of the diabetes prevention trial-type 1 risk score for identifying a preclinical state of type 1 diabetes.

Sosenko JM, Skyler JS, Mahon J, Krischer JP, Beam CA, Boulware DC, Greenbaum CJ, Rafkin LE, Cowie C, Cuthbertson D, Palmer JP; Type 1 Diabetes TrialNet Study Group; Diabetes Prevention Trial-Type 1 Study Group.

Diabetes Care. 2012 Jul;35(7):1552-5. doi: 10.2337/dc12-0011. Epub 2012 Apr 30.

4.

The development, validation, and utility of the Diabetes Prevention Trial-Type 1 Risk Score (DPTRS).

Sosenko JM, Skyler JS, Palmer JP; Diabetes Type 1 TrialNet and Diabetes Prevention Trial-Type 1 Study Groups.

Curr Diab Rep. 2015 Aug;15(8):49. doi: 10.1007/s11892-015-0626-1. Review.

PMID:
26077017
5.

A new approach for diagnosing type 1 diabetes in autoantibody-positive individuals based on prediction and natural history.

Sosenko JM, Skyler JS, DiMeglio LA, Beam CA, Krischer JP, Greenbaum CJ, Boulware D, Rafkin LE, Matheson D, Herold KC, Mahon J, Palmer JP; Type 1 Diabetes TrialNet Study Group; Diabetes Prevention Trial-Type 1 Study Group.

Diabetes Care. 2015 Feb;38(2):271-6. doi: 10.2337/dc14-1813. Epub 2014 Dec 17.

6.

The prediction of type 1 diabetes by multiple autoantibody levels and their incorporation into an autoantibody risk score in relatives of type 1 diabetic patients.

Sosenko JM, Skyler JS, Palmer JP, Krischer JP, Yu L, Mahon J, Beam CA, Boulware DC, Rafkin L, Schatz D, Eisenbarth G; Type 1 Diabetes TrialNet Study Group; Diabetes Prevention Trial-Type 1 Study Group.

Diabetes Care. 2013 Sep;36(9):2615-20. doi: 10.2337/dc13-0425. Epub 2013 Jul 1.

7.

A comparison of the baseline metabolic profiles between Diabetes Prevention Trial-Type 1 and TrialNet Natural History Study participants.

Sosenko JM, Mahon J, Rafkin L, Lachin JM, Krause-Steinrauf H, Krischer JP, Cuthbertson D, Palmer JP, Thompson C, Greenbaum CJ, Skyler JS; Diabetes Prevention Trial-Type 1 and TrialNet Study Groups.

Pediatr Diabetes. 2011 Mar;12(2):85-90. doi: 10.1111/j.1399-5448.2010.00662.x.

8.

A risk score for type 1 diabetes derived from autoantibody-positive participants in the diabetes prevention trial-type 1.

Sosenko JM, Krischer JP, Palmer JP, Mahon J, Cowie C, Greenbaum CJ, Cuthbertson D, Lachin JM, Skyler JS; Diabetes Prevention Trial-Type 1 Study Group.

Diabetes Care. 2008 Mar;31(3):528-33. Epub 2007 Nov 13.

PMID:
18000175
9.

Pancreatic islet autoantibodies as predictors of type 1 diabetes in the Diabetes Prevention Trial-Type 1.

Orban T, Sosenko JM, Cuthbertson D, Krischer JP, Skyler JS, Jackson R, Yu L, Palmer JP, Schatz D, Eisenbarth G; Diabetes Prevention Trial-Type 1 Study Group.

Diabetes Care. 2009 Dec;32(12):2269-74. doi: 10.2337/dc09-0934. Epub 2009 Sep 9.

10.

Prognostic accuracy of immunologic and metabolic markers for type 1 diabetes in a high-risk population: receiver operating characteristic analysis.

Xu P, Beam CA, Cuthbertson D, Sosenko JM, Skyler JS, Krischer JP; DPT-1 Study Group.

Diabetes Care. 2012 Oct;35(10):1975-80. Epub 2012 Jul 11.

11.

Impact of diabetes susceptibility loci on progression from pre-diabetes to diabetes in at-risk individuals of the diabetes prevention trial-type 1 (DPT-1).

Butty V, Campbell C, Mathis D, Benoist C; DPT-1 Study Group.

Diabetes. 2008 Sep;57(9):2348-59. doi: 10.2337/db07-1736. Epub 2008 Jun 12.

12.

The development and utility of a novel scale that quantifies the glycemic progression toward type 1 diabetes over 6 months.

Sosenko JM, Skyler JS, Beam CA, Boulware D, Mahon JL, Krischer JP, Greenbaum CJ, Rafkin LE, Matheson D, Herold KC, Palmer JP; Type 1 Diabetes TrialNet and Diabetes Prevention Trial–Type 1 Study Groups.

Diabetes Care. 2015 May;38(5):940-2. doi: 10.2337/dc14-2787. Epub 2015 Mar 10.

13.

Islet autoantibody seroconversion in the DPT-1 study: justification for repeat screening throughout childhood.

Vehik K, Haller MJ, Beam CA, Schatz DA, Wherrett DK, Sosenko JM, Krischer JP; DPT-1 Study Group.

Diabetes Care. 2011 Feb;34(2):358-62. doi: 10.2337/dc10-1494.

14.

The TrialNet Natural History Study of the Development of Type 1 Diabetes: objectives, design, and initial results.

Mahon JL, Sosenko JM, Rafkin-Mervis L, Krause-Steinrauf H, Lachin JM, Thompson C, Bingley PJ, Bonifacio E, Palmer JP, Eisenbarth GS, Wolfsdorf J, Skyler JS; TrialNet Natural History Committee; Type 1 Diabetes TrialNet Study Group.

Pediatr Diabetes. 2009 Apr;10(2):97-104. doi: 10.1111/j.1399-5448.2008.00464.x. Epub 2008 Sep 24.

PMID:
18823409
15.

Incident dysglycemia and progression to type 1 diabetes among participants in the Diabetes Prevention Trial-Type 1.

Sosenko JM, Palmer JP, Rafkin-Mervis L, Krischer JP, Cuthbertson D, Mahon J, Greenbaum CJ, Cowie CC, Skyler JS; Diabetes Prevention Trial-Type 1 Study Group.

Diabetes Care. 2009 Sep;32(9):1603-7. doi: 10.2337/dc08-2140. Epub 2009 Jun 1.

16.

Performance of HbA1c as an early diagnostic indicator of type 1 diabetes in children and youth.

Vehik K, Cuthbertson D, Boulware D, Beam CA, Rodriguez H, Legault L, Hyytinen M, Rewers MJ, Schatz DA, Krischer JP; TEDDY, TRIGR, Diabetes Prevention Trial–Type 1, and Type 1 Diabetes TrialNet Natural History Study Groups.

Diabetes Care. 2012 Sep;35(9):1821-5. Epub 2012 Jun 14.

17.

Increasing the accuracy of oral glucose tolerance testing and extending its application to individuals with normal glucose tolerance for the prediction of type 1 diabetes: the Diabetes Prevention Trial-Type 1.

Sosenko JM, Palmer JP, Greenbaum CJ, Mahon J, Cowie C, Krischer JP, Chase HP, White NH, Buckingham B, Herold KC, Cuthbertson D, Skyler JS; Diabetes Prevention Trial-Type 1 Study Group.

Diabetes Care. 2007 Jan;30(1):38-42.

PMID:
17192330
18.

Early seroconversion and rapidly increasing autoantibody concentrations predict prepubertal manifestation of type 1 diabetes in children at genetic risk.

Parikka V, Näntö-Salonen K, Saarinen M, Simell T, Ilonen J, Hyöty H, Veijola R, Knip M, Simell O.

Diabetologia. 2012 Jul;55(7):1926-36. doi: 10.1007/s00125-012-2523-3. Epub 2012 Mar 23.

PMID:
22441569
19.

Distribution of C-peptide and its determinants in North American children at risk for type 1 diabetes.

Xu P, Qian X, Schatz DA, Cuthbertson D, Krischer JP; DPT-1 Study Group.

Diabetes Care. 2014 Jul;37(7):1959-65. doi: 10.2337/dc13-2603. Epub 2014 Apr 23.

20.

Number of autoantibodies (against insulin, GAD or ICA512/IA2) rather than particular autoantibody specificities determines risk of type I diabetes.

Verge CF, Gianani R, Kawasaki E, Yu L, Pietropaolo M, Chase HP, Eisenbarth GS.

J Autoimmun. 1996 Jun;9(3):379-83.

PMID:
8816974
Items per page

Supplemental Content

Write to the Help Desk